Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
17 déc. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
12 déc. 2024 08h00 HE
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
27 nov. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
13 nov. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
15 oct. 2024 08h00 HE
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29 août 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31 juil. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09 avr. 2024 12h00 HE
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models